Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas
暂无分享,去创建一个
A. Ashworth | J. Reis-Filho | A. Longatto-Filho | R. Reis | K. Fenwick | A. Mackay | F. Pardal | J. Lopes | N. Tamber | O. Martinho | F. Milanezi | M. Lambros | A. Martins | C. Pinheiro | A. Silva | J. Amorim | Ana Gabriela Silva | A. Longatto‐Filho | Olga Martinho | Albino Martins | Narinder Tamber
[1] I. Blümcke,et al. Spontaneous In Vitro Transformation of Adult Neural Precursors into Stem‐Like Cancer Cells , 2009, Brain pathology.
[2] A. Ashworth,et al. A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines , 2009, Breast Cancer Research and Treatment.
[3] A. Ashworth,et al. The genomic profile of HER2‐amplified breast cancers: the influence of ER status , 2008, The Journal of pathology.
[4] Denis Lacombe,et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[6] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[7] Hanna Göransson,et al. Screening for copy‐number alterations and loss of heterozygosity in chronic lymphocytic leukemia—A comparative study of four differently designed, high resolution microarray platforms , 2008, Genes, chromosomes & cancer.
[8] A. Ashworth,et al. Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast , 2008, The Journal of pathology.
[9] Santosh Kesari,et al. Malignant gliomas in adults. , 2008, The New England journal of medicine.
[10] Anne Vincent-Salomon,et al. ESR1 gene amplification in breast cancer: a common phenomenon? , 2008, Nature Genetics.
[11] R. McLendon,et al. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. , 2008, Neuro-oncology.
[12] T. MacDonald,et al. Protein Expression of Platelet-Derived Growth Factor Receptor Correlates with Malignant Histology and PTEN with Survival in Childhood Gliomas , 2008, Clinical Cancer Research.
[13] Alan Mackay,et al. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines , 2008, Laboratory Investigation.
[14] O. Lingjaerde,et al. ESR1 gene amplification in breast cancer: a common phenomenon? , 2008, Nature Genetics.
[15] C. Hawkins,et al. Tyrosine kinase expression in pediatric high grade astrocytoma , 2008, Journal of Neuro-Oncology.
[16] E. Lander,et al. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.
[17] H. Newton. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors. , 2007, Current opinion in investigational drugs.
[18] Å. Borg,et al. Screening for Copy Number Alterations and Loss of Heterozygosity in Chronic Lymphocytic Leukemia - A Comparative Study of Four Differently Designed, High Resolution Microarray Platforms. , 2007 .
[19] Webster K. Cavenee,et al. Erratum: The 2007 WHO classification of tumours of the central nervous system (Acta Neuropathol (2007) vol. 114 (97-109)) , 2007 .
[20] M. J. van den Bent,et al. Molecular targeted therapies and chemotherapy in malignant gliomas , 2007, Current opinion in oncology.
[21] R. Reis,et al. Molecular alterations of KIT and PDGFRA in GISTs: evaluation of a Portuguese series , 2007, Journal of Clinical Pathology.
[22] Johan Staaf,et al. BIOINFORMATICS ORIGINAL PAPER doi:10.1093/bioinformatics/btm359 Data and text mining , 2022 .
[23] J. Reis-Filho,et al. Molecular Alterations of KIT Oncogene in Gliomas , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.
[24] B. Scheithauer,et al. The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.
[25] Andreas von Deimling,et al. Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme. , 2007, Neuro-oncology.
[26] B. Coe,et al. Resolving the resolution of array CGH. , 2007, Genomics.
[27] E. Holland,et al. Platelet-derived growth factor-mediated gliomagenesis and brain tumor recruitment. , 2007, Neurosurgery clinics of North America.
[28] Alan Mackay,et al. Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation , 2007, Laboratory Investigation.
[29] K. Wong,et al. Expression of oligodendroglial differentiation markers in pilocytic astrocytomas identifies two clinical subsets and shows a significant correlation with proliferation index and progression free survival , 2007, Journal of Neuro-Oncology.
[30] R. McLendon,et al. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas , 2007, Journal of Neuro-Oncology.
[31] A. Paetau,et al. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in Gliomas , 2006, Molecular Cancer Research.
[32] Howard A. Fine,et al. Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 , 2006, Clinical Cancer Research.
[33] C. Heldin,et al. Characterization of an imatinib-sensitive subset of high-grade human glioma cultures , 2006, Oncogene.
[34] S. Vandenberg,et al. PDGFRα-Positive B Cells Are Neural Stem Cells in the Adult SVZ that Form Glioma-like Growths in Response to Increased PDGF Signaling , 2006, Neuron.
[35] C. Dominici,et al. Increased sensitivity to the platelet‐derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF‐BB‐mediated signaling and STI571‐induced Akt inactivation , 2006, Journal of cellular physiology.
[36] A. Buschauer,et al. Platelet-derived growth factor receptor independent proliferation of human glioblastoma cells: selective tyrosine kinase inhibitors lack antiproliferative activity , 2006, Journal of Cancer Research and Clinical Oncology.
[37] A. Ashworth,et al. Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization , 2006, Laboratory Investigation.
[38] E. Holland,et al. Platelet-derived growth factor (PDGF) and glial tumorigenesis. , 2006, Cancer letters.
[39] David N Louis,et al. Molecular pathology of malignant gliomas. , 2006, Annual review of pathology.
[40] A. Longatto-Filho,et al. Molecular Characterization of PDGFR-α/PDGF-A and c-KIT/SCF in Gliosarcomas , 2005, Cellular oncology : the official journal of the International Society for Cellular Oncology.
[41] Allan H Friedman,et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] M. Alonso,et al. Real-Time Quantitative PCR Analysis of Regions Involved in Gene Amplification Reveals Gene Overdose in Low-Grade Astrocytic Gliomas , 2005, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[43] S. Levy,et al. Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[44] H. Joensuu,et al. Amplification of genes encoding KIT, PDGFRα and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme , 2005, The Journal of pathology.
[45] Albino Martins,et al. Overexpression of platelet-derived growth factor receptor α in breast cancer is associated with tumour progression , 2005, Breast Cancer Research.
[46] M. Alonso,et al. Real-time quantitative PCR analysis of gene dosages reveals gene amplification in low-grade oligodendrogliomas. , 2005, American journal of clinical pathology.
[47] K. Franssila,et al. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] R. Reis,et al. Mutation analysis of B-RAF gene in human gliomas , 2005, Acta Neuropathologica.
[49] Christian Hartmann,et al. Pdgfr‐α in 1p/19q LOH oligodendrogliomas , 2004 .
[50] A. Ullrich,et al. The discovery of receptor tyrosine kinases: targets for cancer therapy , 2004, Nature Reviews Cancer.
[51] L. Puricelli,et al. EGF‐R and PDGF‐R, but not bcl‐2, overexpression predict overall survival in patients with low‐grade astrocytomas , 2004, Journal of surgical oncology.
[52] Christian Hartmann,et al. Pdgfr-alpha in 1p/19q LOH oligodendrogliomas. , 2004, International Journal of Cancer.
[53] Tobias Sjöblom,et al. PDGF receptors as cancer drug targets. , 2003, Cancer cell.
[54] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[55] Alex Matter,et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.
[56] M. Israel,et al. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. , 2002, Cancer research.
[57] M. Nistér,et al. Prognostic value of platelet derived growth factor α receptor expression in grade 2 astrocytomas and oligoastrocytomas , 2002, Journal of neurology, neurosurgery, and psychiatry.
[58] Z L Gokaslan,et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.
[59] T. Hunter,et al. Oncogenic kinase signalling , 2001, Nature.
[60] C. Sawyers,et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.
[61] C. James,et al. Amplification of the Platelet‐Derived Growth Factor Receptor‐A (PDGFRA) Gene Occurs in Oligodendrogliomas with Grade IV Anaplastic Features , 2000, Journal of neuropathology and experimental neurology.
[62] Kelvin H. Lee,et al. Genomic analysis. , 2000, Current opinion in biotechnology.
[63] M. Nistér,et al. Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. , 1998, Cancer research.
[64] R. Carroll,et al. Platelet-derived growth factor and its receptor expression in human oligodendrogliomas. , 1998, Neurosurgery.
[65] R. Carroll,et al. Expression of platelet-derived growth factor transcripts in medulloblastomas and ependymomas. , 1996, Pediatric neurosurgery.
[66] D. Louis,et al. Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas. , 1996, Cancer research.
[67] C. Heldin,et al. Platelet‐derived growth factor in human glioma , 1995, Glia.
[68] A. Guha,et al. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop , 1995, International journal of cancer.
[69] K. Plate,et al. Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas. , 1992, Laboratory investigation; a journal of technical methods and pathology.
[70] E. Oldfield,et al. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. , 1992, Cancer research.
[71] C. Heldin,et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. , 1992, Cancer research.
[72] T. Yoshimoto,et al. Amplification of alpha-platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin. , 1992, Oncogene.
[73] C. Heldin,et al. Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines. , 1991, The Journal of biological chemistry.
[74] T. Mapstone. Expression of platelet-derived growth factor and transforming growth factor and their correlation with cellular morphology in glial tumors. , 1991, Journal of neurosurgery.
[75] P. Black,et al. Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance. , 1990, The Journal of clinical investigation.
[76] C. Heldin,et al. Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[77] T. Libermann,et al. Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines. , 1988, Cancer research.
[78] W. Richardson,et al. A role for platelet-derived growth factor in normal gliogenesis in the central nervous system , 1988, Cell.